MEI Pharma (NASDAQ: MEIP) announced top-line data from a randomized Phase II clinical study of its investigational drug candidate Pracinostat ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE